A Novel Multiplex droplet digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens

Recurrent activating point mutations in KRAS are critical drivers in pancreatic cancer and have been attributed to resistance to anti –epidermal growth factor receptor therapy in colorectal cancer. Although KRAS genotyping provides limited clinical utility in the diagnosis and management of pancreatic cancer patients at present, inferences about the fractional abundance of KRAS mutations may inform on tumor purity in traditional ly challenging clinical specimens and their potential use in precision medicine.

Source: Journal of Molecular Diagnostics - November 22, 2018 Category: Pathology Authors: Miguel Alcaide, Matthew Cheung, Kevin Bushell, Sarah E. Arthur, Hui-Li Wong, Joanna Karasinska, Daniel Renouf, David F. Schaeffer, Suzan McNamara, Mathilde Couetoux du Tertre, Gerald Batist, Hagen F. Kennecke, Aly Karsan, Ryan D. Morin Tags: Regular article Source Type: research